These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34709391)

  • 21. Managing prescription drug costs: a case study.
    DuBois RW; Feinberg PE
    Med Interface; 1994 Jun; 7(6):65-8, 70, 74. PubMed ID: 10135321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Copayment coupons undermine formularies.
    Manag Care; 2011 Dec; 20(12):63. PubMed ID: 22259878
    [No Abstract]   [Full Text] [Related]  

  • 23. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variability in drug formularies and implications in decision support.
    Stephens MJ; Finnell JT; Simonaitis L; Overhage JM
    AMIA Annu Symp Proc; 2011; 2011():1327-36. PubMed ID: 22195194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence that value-based insurance can be effective.
    Chernew ME; Juster IA; Shah M; Wegh A; Rosenberg S; Rosen AB; Sokol MC; Yu-Isenberg K; Fendrick AM
    Health Aff (Millwood); 2010; 29(3):530-6. PubMed ID: 20093294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
    Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
    Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription drug accessibility and affordability in the United States and abroad.
    Morgan S; Kennedy J
    Issue Brief (Commonw Fund); 2010 Jun; 89():1-12. PubMed ID: 20614652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incentive-based formularies.
    Thomas CP
    N Engl J Med; 2003 Dec; 349(23):2186-8. PubMed ID: 14657424
    [No Abstract]   [Full Text] [Related]  

  • 29. National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration.
    Hartman M; Martin AB; Benson J; Catlin A;
    Health Aff (Millwood); 2013 Jan; 32(1):87-99. PubMed ID: 23297275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulary considerations: the past, present, and future.
    Leber MB
    Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP490-SP491. PubMed ID: 29087661
    [No Abstract]   [Full Text] [Related]  

  • 31. Recognize the role of employers.
    French M
    Healthc Pap; 2004; 4(3):46-50; discussion 68-72. PubMed ID: 15114069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slowdown in prescription drug spending won't last.
    Manag Care; 2013 Nov; 22(11):49. PubMed ID: 24409532
    [No Abstract]   [Full Text] [Related]  

  • 34. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
    McLeod L; Bereza BG; Shim M; Grootendorst P
    Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.
    Buttorff C; Andersen MS; Riggs KR; Alexander GC
    Health Aff (Millwood); 2015 Mar; 34(3):467-76. PubMed ID: 25732498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National trends in prescription drug expenditures and projections for 2015.
    Schumock GT; Li EC; Suda KJ; Wiest MD; Stubbings J; Matusiak LM; Hunkler RJ; Vermeulen LC
    Am J Health Syst Pharm; 2015 May; 72(9):717-36. PubMed ID: 25873620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CMS rules on employers, formularies, PPOs raise concerns.
    Med Health; 2004 Sep; 58(34):2-3. PubMed ID: 15487559
    [No Abstract]   [Full Text] [Related]  

  • 38. PBMs Just Say No to Some Drugs--But Not to Others.
    Reinke T
    Manag Care; 2015 Apr; 24(4):24-5. PubMed ID: 26489172
    [No Abstract]   [Full Text] [Related]  

  • 39. Data watch. How employers are tackling Rx costs.
    Bus Health; 1999 Jul; 17(7):48. PubMed ID: 10539172
    [No Abstract]   [Full Text] [Related]  

  • 40. Access and cost implications of state limitations on Medicaid reimbursement for pharmaceuticals.
    Schweitzer SO; Shiota SR
    Annu Rev Public Health; 1992; 13():399-410. PubMed ID: 1599596
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.